Who
Tony Goodman
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Adial Pharmaceuticals.
In numbers
- Trades disclosed
- 11
- Buys
- 1
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Jul 2018
- Last trade
- 7 Apr 2026
- Last filed
- 9 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Apr 2026filed 9 Apr 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —26,510 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —26,510 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —94,000 at $0.00 | filing |
| 25 Mar 2024filed 27 Mar 2024 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 27 Jun 2022filed 28 Jun 2022 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 23 Feb 2022filed 25 Feb 2022 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 8 Feb 2021filed 10 Feb 2021 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 3 Mar 2020filed 5 Mar 2020 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 31 Jul 2018filed 2 Aug 2018 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —7,000 | filing |
| 31 Jul 2018filed 2 Aug 2018 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Bought | —7,000 | filing |
News
No headline names them, or the companies they trade most, lately.